<DOC>
	<DOCNO>NCT01721772</DOCNO>
	<brief_summary>The purpose study compare clinical benefit , measure overall survival , nivolumab . dacarbazine patient previously untreated , unresectable , metastatic melanoma</brief_summary>
	<brief_title>Study Nivolumab ( BMS-936558 ) Compared With Dacarbazine Untreated , Unresectable , Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman â‰¥18 year age Eastern Cooperative Oncology Group Performance Status 0 1 Untreated histologically confirm unresectable Stage III Stage IV melanoma , per stag system American Joint Committee Cancer Measurable disease per Response Evaluation Criteria Solid Tumors 1.1 Tumor tissue unresectable metastatic site disease must provide biomarker analysis Known BRAF wildtype , per regionally acceptable V600 mutational status test . BRAF mutant patient indeterminate unknown BRAF status permit randomize Active brain metastasis leptomeningeal metastasis Ocular melanoma Any active , know , suspect autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>